Out-Licencing
Transforming Proven Science into Patient Solutions
At Green Park Pharma, we are committed to advancing patient care by reimagining established medicines through innovative drug delivery systems and speciality formulations.
Our mission is to address real-world needs, especially for those who struggle with traditional pill formats. By offering new, patient-friendly options, we can make a tangible difference.
Our Out-Licensing Vision
Green Park Pharma is more than an in-licensing business. We are actively building a proprietary pipeline of late-stage assets, with a clear ambition to bring our innovations to patients worldwide through strategic partnerships. Our current focus includes gastroenterology and other areas of unmet clinical need, but our expertise and technologies have broad applicability across multiple therapeutic categories.
We are continuously expanding our pipeline, with additional late-stage assets in development. As these products approach regulatory milestones, we will seek partners who share our vision for improving patient outcomes and who can help maximise the reach and impact of our innovations.
Why Partner with Green Park Pharma?
Proven Team, Agile Approach
Our leadership team has successfully launched over 40 pharmaceutical products across the UK and international markets.
As a focused, agile organisation, we provide the dedicated attention and drive that larger companies may not be able to match, ensuring each asset receives the priority it deserves.
Flexible, Collaborative Partnerships
We seek partners who are committed to making our assets a strategic priority, typically specialty or regional pharmaceutical companies with established commercial and regulatory capabilities.
Our approach is flexible, supporting regional or global agreements, and we are open to co-development or joint-venture models where there is a strong strategic fit
Innovative, Patient-Centric Pipeline
Our proprietary liquid formulation technology addresses the needs of patients who cannot tolerate standard oral medicines, offering stable, ready-to-use alternatives that improve adherence and quality of life.
What We Offer
Ideal Partner Profile
We are interested in speaking with a wide range of organisations with teh following specilisms
Contract manufacturing organisations (CMOs) with R&D capabilities interested in technology transfer and local market execution, particularly in the US and other
high-growth regions.
Organisations with established regulatory, reimbursement, and commercial capabilities, for whom our assets will
be a priority.
Speciality and regional pharmaceutical companies seeking to enhance their portfolios with innovative,
high-impact products.
Our Pipeline
Our late-stage pipeline is designed to deliver new options for patients with unmet needs, with a particular emphasis on liquid formulations for those who cannot tolerate standard oral medicines. We are committed to expanding into additional therapeutic areas as our development progresses.
Details on specific products and partnering opportunities are available to qualified partners upon request and under appropriate confidentiality agreements.
